Literature DB >> 33409833

Serodiagnosis of Lyme borreliosis-is IgM in serum more harmful than helpful?

Henrik Hillerdal1,2, Anna J Henningsson3,4,5,6.   

Abstract

Interpretation of serological findings in suspected Lyme borreliosis (LB) may be challenging and IgM reactivities in serum are often unspecific (false positive). There is a risk for overdiagnosis of LB, inadequate use of antibiotics, and potential delay of proper diagnosis. In this study, we evaluated the diagnostic value of IgM analysis in serum and IgM antibody index (AI) in LB diagnosis. This was a retrospective observational study regarding Borrelia-specific antibodies in serum and Borrelia-specific AI in LB investigations being made during 2017 in Jönköping County, Sweden. Medical records of 610 patients with detectable anti-Borrelia antibodies in serum (IgM and/or IgG) and 15 patients with elevated Borrelia-specific AI were retrospectively scrutinized, and the compliance to current European recommendations was assessed. Among the 610 patients, only 30% were tested according to the European recommendations. Within this group of tests taken correctly, 50% of the LB diagnoses in patients with isolated IgM reactivity in serum were retrospectively assessed as incorrect (LB unlikely). Three pediatric patients with clinical and laboratory findings suggestive of Lyme neuroborreliosis (LNB) had elevated IgM AI alone. Serological testing without distinct clinical signs/symptoms consistent with LB contributes to most misdiagnoses. Isolated IgM positivity in serum shows limited clinical value and needs further assessment before being reported by the laboratory. Detection of IgM in combination with IgG antibodies in serum shows no clinical enhancement for correct LB diagnosis compared to isolated IgG positivity. However, Borrelia-specific IgM AI may be important for sensitivity in early LNB.

Entities:  

Keywords:  Clinical; Diagnostics; IgG; IgM; Lyme borreliosis; Serology

Year:  2021        PMID: 33409833     DOI: 10.1007/s10096-020-04093-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Evaluation of commercial screening tests and blot assays for the diagnosis of Lyme borreliosis.

Authors:  Laurent Busson; Marijke Reynders; Sigi Van den Wijngaert; Hafid Dahma; Marc Decolvenaer; Liesbet Vasseur; Olivier Vandenberg
Journal:  Diagn Microbiol Infect Dis       Date:  2012-05-04       Impact factor: 2.803

2.  Lyme borreliosis: clinical case definitions for diagnosis and management in Europe.

Authors:  G Stanek; V Fingerle; K-P Hunfeld; B Jaulhac; R Kaiser; A Krause; W Kristoferitsch; S O'Connell; K Ornstein; F Strle; J Gray
Journal:  Clin Microbiol Infect       Date:  2011-01       Impact factor: 8.067

3.  Borrelia burgdorferi sensu lato serology in the Netherlands: guidelines versus daily practice.

Authors:  J Coumou; J W R Hovius; A P van Dam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-17       Impact factor: 3.267

4.  Chronic polyneuropathy and Lyme disease.

Authors:  A Mygland; T Skarpaas; U Ljøstad
Journal:  Eur J Neurol       Date:  2006-11       Impact factor: 6.089

Review 5.  To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis.

Authors:  R B Dessau; A P van Dam; V Fingerle; J Gray; J W Hovius; K-P Hunfeld; B Jaulhac; O Kahl; W Kristoferitsch; P-E Lindgren; M Markowicz; S Mavin; K Ornstein; T Rupprecht; G Stanek; F Strle
Journal:  Clin Microbiol Infect       Date:  2017-09-05       Impact factor: 8.067

6.  C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden.

Authors:  I Tjernberg; G Krüger; I Eliasson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 5.103

7.  Utilization of serology for the diagnosis of suspected Lyme borreliosis in Denmark: survey of patients seen in general practice.

Authors:  Ram B Dessau; Jette M Bangsborg; Tove Ejlertsen; Sigurdur Skarphedinsson; Henrik C Schønheyder
Journal:  BMC Infect Dis       Date:  2010-11-01       Impact factor: 3.090

8.  Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots.

Authors:  C W Ang; D W Notermans; M Hommes; A M Simoons-Smit; T Herremans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-27       Impact factor: 3.267

  8 in total
  4 in total

1.  The Performance of Nine Commercial Serological Screening Assays for the Diagnosis of Lyme Borreliosis: a Multicenter Modified Two-Gate Design Study.

Authors:  B J A Hoeve-Bakker; Mark Jonker; Afke H Brandenburg; P Martijn den Reijer; Foekje F Stelma; Alje P van Dam; Tamara van Gorkom; Karen Kerkhof; Steven F T Thijsen; Kristin Kremer
Journal:  Microbiol Spectr       Date:  2022-03-17

2.  Introduction of IgM testing for the diagnosis of acute Lyme borreliosis: a study of the benefits, limitations and costs.

Authors:  Greg Joyner; Sally Mavin; Rachel Milner; Chin Lim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-28       Impact factor: 3.267

3.  Persistent Anti-Borrelia IgM Antibodies without Lyme Borreliosis in the Clinical and Immunological Context.

Authors:  Mateusz Markowicz; Michael Reiter; Jutta Gamper; Gerold Stanek; Hannes Stockinger
Journal:  Microbiol Spectr       Date:  2021-12-22

4.  An intervention in general practice to improve the management of Lyme borreliosis in Denmark.

Authors:  Fredrikke Christie Knudtzen; Thøger Gorm Jensen; Nanna Skaarup Andersen; Isik Somuncu Johansen; Joppe W Hovius; Sigurdur Skarphédinsson
Journal:  Eur J Public Health       Date:  2022-06-01       Impact factor: 4.424

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.